Soleno Therapeutics to Participate in Upcoming Investor Conferences

May 22, 2024

REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences:

Event Jefferies Global Healthcare Conference
Day Wednesday, June 5, 2024
Time: 11:30 AM Eastern Time
Event: Goldman Sachs 45th Annual Global Healthcare Conference
Day: Tuesday, June 11, 2024
Time: 4:00 PM ET

A live audio webcast and replay of the events will be available in the Investors section on the Company’s website at

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of PWS, recently completed its Phase 3 development program to support a planned NDA submission. For more information, please visit

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC

Primary Logo

Source: Soleno Therapeutics